3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Colorectal Neoplasms
13
Rectal Neoplasms
5
Neoplasm Metastasis
4
Cholangiocarcinoma
4
Stomach Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Hepatocellular
3
Biliary Tract Neoplasms
3
Adenocarcinoma Of Esophagus
3
Ovarian Neoplasms
2
Neoplasms
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Recurrence
1
Pathologic Complete Response
1
Lung Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Central Nervous System Neoplasms
1
Carcinoma, Basal Cell
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Advanced Rectal Cancer
1
Adenocarcinoma of the Lower Rectum
1
Adenocarcinoma
1
Interventions
fludarabine
4
Cyclophosphamide
4
fludarabine phosphate
3
Melphalan
3
pembrolizumab
2
obinutuzumab
2
blinatumomab
2
Rituximab
2
Radiotherapy
2
Lenalidomide
2
Capecitabine
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
sacituzumab govitecan
1
palbociclib
1
nilotinib
1
isatuximab
1
avelumab
1
atezolizumab
1
acalabrutinib
1
Whole-Body Irradiation
1
Trastuzumab
1
Sirolimus
1
Neoadjuvant Therapy
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Folfox protocol
×
90 days
×
Clear all
No trials found.